Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Other Operating Expenses (2016 - 2025)

Cytosorbents' Other Operating Expenses history spans 15 years, with the latest figure at $22.5 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $22.5 million for Q4 2025, up 691.04% from a year ago — trailing twelve months through Dec 2025 was $5.5 million (up 123.65% YoY), and the annual figure for FY2025 was $2.1 million, up 109.11%.
  • Other Operating Expenses for Q4 2025 was $22.5 million at Cytosorbents, up from -$6.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $22.5 million in Q4 2025 to a low of -$6.9 million in Q1 2024.
  • The 5-year median for Other Operating Expenses is $625361.5 (2021), against an average of -$614405.4.
  • The sharpest move saw Other Operating Expenses tumbled 1276.29% in 2024, then surged 691.04% in 2025.
  • Year by year, Other Operating Expenses stood at $641205.0 in 2021, then rose by 18.3% to $758569.0 in 2022, then tumbled by 548.51% to -$3.4 million in 2023, then dropped by 12.07% to -$3.8 million in 2024, then surged by 691.04% to $22.5 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $22.5 million, -$6.0 million, and -$5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.